PMID- 24080644
OWN - NLM
STAT- MEDLINE
DCOM- 20140619
LR  - 20220419
IS  - 1098-6596 (Electronic)
IS  - 0066-4804 (Print)
IS  - 0066-4804 (Linking)
VI  - 57
IP  - 12
DP  - 2013 Dec
TI  - High-dose daptomycin therapy for left-sided infective endocarditis: a prospective 
      study from the international collaboration on endocarditis.
PG  - 6213-22
LID - 10.1128/AAC.01563-13 [doi]
AB  - The use of daptomycin in Gram-positive left-sided infective endocarditis (IE) has 
      significantly increased. The purpose of this study was to assess the influence of 
      high-dose daptomycin on the outcome of left-sided IE due to Gram-positive 
      pathogens. This was a prospective cohort study based on 1,112 cases from the 
      International Collaboration on Endocarditis (ICE)-Plus database and the 
      ICE-Daptomycin Substudy database from 2008 to 2010. Among patients with 
      left-sided IE due to Staphylococcus aureus, coagulase-negative staphylococci, and 
      Enterococcus faecalis, we compared those treated with daptomycin (cohort A) to 
      those treated with standard-of-care (SOC) antibiotics (cohort B). The primary 
      outcome was in-hospital mortality. Time to clearance of bacteremia, 6-month 
      mortality, and adverse events (AEs) ascribable to daptomycin were also assessed. 
      There were 29 and 149 patients included in cohort A and cohort B, respectively. 
      Baseline comorbidities did not differ between the two cohorts, except for a 
      significantly higher prevalence of diabetes and previous episodes of IE among 
      patients treated with daptomycin. The median daptomycin dose was 9.2 mg/kg of 
      body weight/day. Two-thirds of the patients treated with daptomycin had failed a 
      previous antibiotic regimen. In-hospital and 6-month mortalities were similar in 
      the two cohorts. In cohort A, median time to clearance of methicillin-resistant 
      S. aureus (MRSA) bacteremia was 1.0 day, irrespective of daptomycin dose, 
      representing a significantly faster bacteremia clearance compared to SOC (1.0 
      versus 5.0 days; P < 0.01). Regimens with higher daptomycin doses were not 
      associated with increased incidence of AEs. In conclusion, higher-dose daptomycin 
      may be an effective and safe alternative to SOC in the treatment of left-sided IE 
      due to common Gram-positive pathogens.
FAU - Carugati, Manuela
AU  - Carugati M
AD  - Department of Clinical Science, University of Milan, Luigi Sacco Hospital, Milan, 
      Italy.
FAU - Bayer, Arnold S
AU  - Bayer AS
FAU - Miro, Jose M
AU  - Miro JM
FAU - Park, Lawrence P
AU  - Park LP
FAU - Guimaraes, Armenio C
AU  - Guimaraes AC
FAU - Skoutelis, Athanasios
AU  - Skoutelis A
FAU - Fortes, Claudio Q
AU  - Fortes CQ
FAU - Durante-Mangoni, Emanuele
AU  - Durante-Mangoni E
FAU - Hannan, Margaret M
AU  - Hannan MM
FAU - Nacinovich, Francisco
AU  - Nacinovich F
FAU - Fernandez-Hidalgo, Nuria
AU  - Fernandez-Hidalgo N
FAU - Grossi, Paolo
AU  - Grossi P
FAU - Tan, Ru-San
AU  - Tan RS
FAU - Holland, Thomas
AU  - Holland T
FAU - Fowler, Vance G Jr
AU  - Fowler VG Jr
FAU - Corey, Ralph G
AU  - Corey RG
FAU - Chu, Vivian H
AU  - Chu VH
CN  - International Collaboration on Endocarditis
LA  - eng
GR  - K24 AI093969/AI/NIAID NIH HHS/United States
GR  - K24-AI093969/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20130930
PL  - United States
TA  - Antimicrob Agents Chemother
JT  - Antimicrobial agents and chemotherapy
JID - 0315061
RN  - 0 (Anti-Bacterial Agents)
RN  - NWQ5N31VKK (Daptomycin)
SB  - IM
MH  - Aged
MH  - Anti-Bacterial Agents/*therapeutic use
MH  - Daptomycin/*therapeutic use
MH  - Endocarditis, Bacterial/*drug therapy
MH  - Enterococcus faecalis/physiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Staphylococcus aureus/physiology
PMC - PMC3837915
EDAT- 2013/10/02 06:00
MHDA- 2014/06/20 06:00
PMCR- 2014/06/01
CRDT- 2013/10/02 06:00
PHST- 2013/10/02 06:00 [entrez]
PHST- 2013/10/02 06:00 [pubmed]
PHST- 2014/06/20 06:00 [medline]
PHST- 2014/06/01 00:00 [pmc-release]
AID - AAC.01563-13 [pii]
AID - 01563-13 [pii]
AID - 10.1128/AAC.01563-13 [doi]
PST - ppublish
SO  - Antimicrob Agents Chemother. 2013 Dec;57(12):6213-22. doi: 10.1128/AAC.01563-13. 
      Epub 2013 Sep 30.